Bardet-Biedl Syndrome Pipeline, Emerging therapies and Drugs by DelveInsight

Bardet-Biedl Syndrome Pipeline, Emerging therapies and Drugs by DelveInsight

DelveInsight has launched a new report on Bardet-Biedl Syndrome Pipeline


Bardet–Biedl syndrome (BBS) is an autosomal recessive inherited condition that affects many parts of the body. People with this syndrome have progressive visual impairment due to cone‐rod dystrophy; extra fingers or toes (polydactyly); truncal obesity; decreased function of the male gonads (hypogonadism); kidney abnormalities; and learning difficulties.


Request for free sample copy-


Bardet-Biedl Syndrome Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities


Bardet-Biedl Syndrome Emerging Therapy

As there is no cure for this disease, the available therapeutics treatment options in Bardet–Biedl Syndrome landscape vary from individual to individual, aiming to reduce associated comorbidities. The dynamics of the Bardet–Biedl Syndrome market is anticipated to change in the coming years owing to the approval of the upcoming therapy.


Marketed drugs included in the report

  • Setmelanotide: Rhythm Pharmaceutical


Bardet-Biedl Syndrome Treatment

Currently, there is no cure for Bardet–Biedl syndrome. Treatment generally focuses on the specific signs and symptoms in each individual. A multidisciplinary approach is required to manage this pleiotropic condition effectively. Some of the physical abnormalities associated with BBS can be corrected with surgery, including extra digits, and some genitourinary abnormalities and congenital heart defects. As with any genetic condition, genetic counseling is recommended for affected individuals and their families.


Bardet-Biedl Syndrome Symptoms

The symptoms of Bardet-Biedl Syndrome include:

  • Truncal obesity
  • Intellectual impairment
  • Renal anomalies
  • Polydactyly
  • Retinal degeneration
  • Hypogenitalism


Bardet-Biedl Syndrome Key Questions Answered

  • How many companies are developing Bardet-Biedl Syndrome drugs?
  • How many Bardet-Biedl Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bardet-Biedl Syndrome?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bardet-Biedl Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bardet-Biedl Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?


Key player of Bardet-Biedl Syndrome Pipeline Report

  • Rhythm Pharmaceuticals


Request for free sample copy-


Table of content

  • Introduction
  • Executive Summary
  • Bardet-Biedl Syndrome: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Bardet-Biedl Syndrome – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Bardet-Biedl Syndrome Collaboration Deals
  • Late Stage Products (Phase III)
  • Setmelanotide: Rhythm Pharmaceuticals
  • Inactive Products
  • Bardet-Biedl Syndrome Key Companies
  • Bardet-Biedl Syndrome Key Products
  • Bardet-Biedl Syndrome- Unmet Needs
  • Bardet-Biedl Syndrome- Market Drivers and Barriers
  • Bardet-Biedl Syndrome- Future Perspectives and Conclusion
  • Bardet-Biedl Syndrome Analyst Views
  • Bardet-Biedl Syndrome Key Companies
  • Appendix


Related Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States